Claudin18.2 a 🔥 🎯 in gastric/GOJ adenocarcinoma with many approaches including ADCs, mAb, Cellular therapies being developed. Hanneke van Laarhoven Look forward to sharing data from next gen ADC IBI343 in Phase I trial from 🇨🇳🇦🇺 on Saturday #ESMOGI24 The Kinghorn Cancer Centre NECTA

Excellent discussion (as always) of CM8HW by Chiara Cremolini . Cross-trial comparisons: “don’t do this at home. But we do it anyway.” #ESMOGI24 ESMO - Eur. Oncology #ESMOambassadors

New targets in immunotherapy beyond CTL4 and PD(L)1 - New targets and new drugs #EMSOGI24 👉Overcoming multiple resistance mechanisms to ICI 👉finding new ways to enhance immune responses 👉🎯: IL-2, LAG-3, TIM-3, TIGIT, B7-H3, CD137... #ESMOAmbassadors ESMO - Eur. Oncology

Amazing perspective on #TherapeuticCancerVaccine for #GastrointestinalCancers by #LuigiBuonaguro at #ESMOGI24 Amazing steps taken until now, finally materialising in clinical trials but still lots to do 🤞🏻 ESMO - Eur. Oncology #ESMOAmbassadors

Neoadjuvant nivolumab + ipilimumab in MSI-H/MMR rectal tumors #EMSOGI24 🔎 ECOG-ACRIN EA2201, 14 pts 👉pCR & cCR: 57% 👉TRAEs ≥3° 35% 👉re-design: 4cycles N/I, W&W #ESMOAmbassadors ESMO - Eur. Oncology

Great discussion by Juan OConnor in the mini-oral session #ESMOGI24. Putting NEST-1 and ECOG /study into perspective. 🙏 also for highlighting our #TARZAN trial with atezo/bev in #rectalcancer for organ preservation (42% OP rate in 38 pMMR pts). #ESMOambassadors ESMO - Eur. Oncology

Anti-claudin 18.2 ADC IBI343 in solid tumors & G/GEJ AC #ESMOGI24 🔎phsI study 👉TRAEs ≥ 3° 49% 👉ORR 41%, DCR 89% 👉mPFS 5.5 mo mOS not mature 🧐Encouraging activity, phs-3 initiated #ESMOAmbassadors ESMO - Eur. Oncology

The ESMO GI meeting has been very educating and innovative. We had found many opportunities to improve our knowledge and to discuss new frontiers for gastrointestinal cancer treatment ESMO - Eur. Oncology ESOncology European Society of Coloproctology Acıbadem Sağlık Acıbadem Üniversitesi TKRCD

How do mismatch repair-deficient (MMRd) cancers trade off the evolutionary costs and benefits of elevated mutation rates? Delighted to share our paper on adaptive mutability in MMRd colorectal cancer (CRC) Nature Genetics nature.com/articles/s4158… Tweetorial 🧵below

Thank you @ACPGBI Jim Tiernan for inviting me to give talk to 200+ CRC surgeons about the NEOPRISM-CRC trial. Also for Elaine Burns trying to keep me to ‘ASCO’ time limits ⏱️😉 Lots of questions and not all the answers (yet)!

Beautiful study from UCL Cancer Institute colleagues Hamzeh Kay Marnix Jansen demonstrating how MSI CRC tumours toggle hypermutable homopolymer runs in MSH6 and MSH3 to regulate immune surveillance nature.com/articles/s4158…

🙏🙏 GI Oncology Now for asking me 3 broad questions about the rationale of the NEOPRISM-CRC design, translational objectives, clinical and research challenges too. UCLH UCL Cancer Institute ECMC Network Cancer Research UK Marnix Jansen Mariam Jamal-Hanjani Quezada Lab Chris Tape buff.ly/4eJMGKA

Abstract titles for #ESMO24 now online! Full NICHE-3 cohort (59 pts with dMMR colon cancer treated with neoadj nivo/rela) will be presented in proferred paper session + more neoadj IO from Imhotep, and wonderful Jenny Seligmann as discussant. Stay tuned for more exciting💥💥💥news!

The genomic landscape of 2,023 colorectal cancers nature.com/articles/s4158…

From the August issue: Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells. bit.ly/3yN4ip3 Gabriele Picco Mathew Garnett Garnett Lab Wellcome Sanger Institute

Permission to post was granted 😊 by host. Early phase investigators participating in #foodeffect (or is it 🍷effect?) dose escalation cohort 😃. #Singapore 🇸🇬 #DavidTan Kai-Keen Shiu

Arrived in #Singapore APGCS2024 to give an update on IO for MSI-H CRC and some hope for patients living with MSS CRC too. Judging by today’s UGI session/MDT debates with Raghav Sundar, Shaheenah Dawood et al, I’m looking forward to be challenged! Shuting Han Iain Tan, NCCS/GIS/Duke-NUS/STCC 🧐

Good times for stomach and brain for sure. The chilli crab was shiok, the beer cold and the conversation was…well very fun, sometimes provocative but also some helpful career advice/mentoring too! See you soon in Barcelona and before the year is out at ESMO Asia! 🤝🤝

🙏🙏 Adele Roberts and Kate Holderness for visiting our UCL Cancer Institute labs; including seeing some NEOPRISM-CRC organoids happily growing too! You both asked great questions about early onset GI cancers. Kudos for running the 🌍, raising awareness + money to support #CancerResearch

Privileged to work with great friends and colleagues in the clinic, wards and research labs UCLH UCL Cancer Institute who keep me grounded and focused with humour, roasting and other means! Have to include the #JansenLab research team selfie pic here too.